Application of Eryngiolide A in medicines curing yellow fever virus infection

A yellow fever virus and drug technology, applied in the field of biomedicine, to achieve the effect of effective prevention and treatment, outstanding substantive characteristics, huge social benefits and research value

Inactive Publication Date: 2013-06-05
吴俊华
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there have been no cases reported in China, but this does not make us relax our vigilance against the virus, because China's climate and geographical environment are complex, and there are many

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Eryngiolide A in medicines curing yellow fever virus infection
  • Application of Eryngiolide A in medicines curing yellow fever virus infection
  • Application of Eryngiolide A in medicines curing yellow fever virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1: Preparation of the compound Eryngiolide A tablet involved in the present invention:

[0037] Take 20 grams of compound Eryngiolide A, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tabletting machine.

Embodiment 2

[0038] Embodiment 2: the preparation of the compound Eryngiolide A capsule of the present invention:

[0039] Get 20 grams of compound Eryngiolide A, add conventional auxiliary materials for preparing capsules such as 180 grams of starch, mix well, and pack into capsules to make 1000 tablets.

[0040] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0042] A kind of application of Eryngiolide A in the preparation treatment or prevention yellow fever virus infection medicine, its steps are:

[0043] A. Toxicity test of Eryngiolide A on Vero cells

[0044] Vero cells (African green monkey kidney cells) are susceptible cells to YFV.

[0045] The experimental steps are as follows:

[0046] 1: Inoculate Vero cells: Use DMEM medium containing 10% (v / v) fetal bovine serum to make a single cell suspension, inoculate 1000-10000 cells per well into a 96-well cell culture plate, and inoculate a volume of 100ul per well ;

[0047] 2: Culture Vero cells: at 37°C, 5% (v / v) CO 2 Under culture conditions, cultivate for 2 days;

[0048] 3: Add Eryngiolide A: Discard the DMEM medium in each well, add 100ul to each well and dilute to the corresponding concentration with DMEM medium containing 10% (v / v) fetal bovine serum (0uM, 0.4uM, 1.2 uM, 3.7uM, 11uM, 33uM, 100uM, 300uM) of Eryngiolide A, add 100ul of DMEM medium containing 10% (v / v...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of Eryngiolide A in preparation of medicines curing or preventing yellow fever virus infection. The Eryngiolide A can effectively inhibit proliferation of the yellow fever virus, but has small toxicity to cells, can be further developed into medicines curing disease caused by the yellow fever virus, and has broad application prospect. Use of the Eryngiolide A in preparation of medicines curing the Alzheimer disease is made public for the first time, the skeleton type is completely novel, and the Eryngiolide A has an unexpectedly high yellow fever virus inhibitory activity, probability of other compounds giving any revelation for the Eryngiolide A does not exist, outstanding substantive features are provided, meanwhile, prominent improvement is evidently possessed in preventing and curing the yellow fever virus infection.

Description

technical field [0001] The invention belongs to the field of biomedicine, and more specifically relates to the application of Eryngiolide A in the preparation of medicines for treating or preventing yellow fever virus infection. Background technique [0002] Yellow fever virus (YFV) is a member of the Flavivirus genus in the family Flaviviridae. Yellow fever virus causes yellow fever, an acute infectious disease. Yellow fever has been designated as a quarantine infectious disease internationally, and China has also designated it as a Class A infectious disease. In 1648, an epidemic of yellow fever was first confirmed in the weekly YUCATAN peninsula. From the 17th to the 19th century, the disease was brought to Europe and North America through transportation. In almost two centuries, yellow fever became one of the most serious plagues in some parts of the United States, Africa, and Europe, causing a large number of deaths. Since the 20th century, the disease has not occurr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/365A61P31/14
CPCY02A50/30
Inventor 冯怡邱翔宇周未末吴俊华
Owner 吴俊华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap